Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2010

 

 

Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)

 

 

000-50679

(Commission File Number)

 

Delaware   77-0487658

(State or other jurisdiction

of incorporation)

 

(I.R.S. Employer

Identification No.)

149 Commonwealth Drive

Menlo Park, CA 94025

(Address of principal executive offices, with zip code)

(650) 327-3270

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders

On June 23, 2010, we held our annual meeting of stockholders to consider and vote on proposals to elect directors to hold office until our annual meeting of stockholders in 2011 and until their successors are elected and qualified and to ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young, LLP, as our independent registered public accounting firm for our fiscal year ending December 31, 2010.

The total number of shares voted at the annual meeting was 59,943,135. The voting on the two matters is set forth below:

Proposal 1 – Election of Directors

The following directors were elected to hold office until our annual meeting of stockholders in 2011 and until their successors are elected and qualified.

 

Director:

   For    Withheld    Broker
Non-Votes

G. Leonard Baker, Jr.

   51,113,270    540,770    8,289,095

Joseph K. Belanoff, M.D.

   51,620,888    33,152    8,289,095

Joseph C. Cook, Jr.

   51,601,473    52,567    8,289,095

Patrick G. Enright

   51,321,580    332,460    8,289,095

James A. Harper

   51,114,020    540,020    8,289,095

David L. Mahoney

   51,111,720    542,320    8,289,095

James N. Wilson

   49,757,432    1,896,608    8,289,095

Proposal 2 – Proposal to ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young, LLP, as our independent registered public accounting firm for our fiscal year ending December 31, 2010:

 

For

   58,727,807

Against

   87,301

Abstain

   1,128,027

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CORCEPT THERAPEUTICS INCORPORATED
Date: June 25, 2010     By:  

/S/    CAROLINE M. LOEWY        

      Caroline M. Loewy
      Chief Financial Officer

 

3